Contact

Category: Sciences

  • IATI optimistic life sciences recovery will continue

    •

    Investor Empires

    85 % of the higher numbers in investment capital funds in the vital Israel sector (medical devices, digital health, biotechnology and pharmaceutical preparations) see investments where foreign companies and funds are increasing in 2025 compared to 2024. PWC ISRAEL, and IVC data, for the International Mixiii International Science and Health…

  • US FDA puts Kezar Life Sciences’ lupus treatment trial on hold after patient deaths By Reuters

    •

    Investor Empires

    (Reuters) – The US Food and Drug Administration imposed a clinical suspension on the drug Kezar Life Sciences (NASDAQ:)’ trial of an experimental drug for lupus, the company said Friday. The FDA’s decision comes after the company said it had temporarily halted a mid-stage trial of the drug, zetomipzomib, to…

  • Cassava Sciences stock tumbles as CEO Remi Barbier resigns (NASDAQ:SAVA)

    •

    Investor Empires

    Cassava ScienceNASDAQ:SAVAGeneral Electric Automotive Co. announced changes to its executive leadership on Wednesday, with Richard Barry taking over as the company’s chief executive officer and executive chairman of the board. The neuroscience-focused pharmaceutical company is researching a new drug. Permanent CEO to replace Remi Barbier who resigned from the company…

  • Gilead Sciences stock upgraded by Raymond James on strong growth outlook for new drugs By Investing.com

    •

    Investor Empires

    On Monday, Raymond James changed its stance on Gilead Sciences Inc. (NASDAQ:GIL) stock, upgrading it from “market perform” to “outperform.” The firm also set a $93.00 price target for the biopharmaceutical company. This update is bolstered by promising data from the PURPOSE-1 study of lenacapavir, a long-acting HIV pre-exposure prophylaxis…